This phase II trial is evaluating the safety and effectiveness of an immunotherapy (Pembrolizumab) in patients with high risk, non-muscle invasive bladder cancer, who have not responded to prior therapy.
This trial is treating patients with bladder cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
All participants will receive intravenous Pembrolizumab (200mg) once every three weeks, for up to two years.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More